Should I Buy AMRX? AMRX 2026 Analysis

Should You Buy Amneal Pharmaceuticals Inc (AMRX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

14.520

1 Day change

-1.69%

52 Week Range

15.000

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Buy now for a near-term (weeks-to-1 month) move: technical trend is bullish and Wall Street targets cluster at $15 (~7% upside from ~$13.97).
Options positioning is extremely call-skewed, reinforcing a bullish sentiment backdrop.
Near-term price action may be choppy (pattern model slightly negative next day/week), but the 1-month pattern bias is strongly positive.
Intellectia Proprietary Trading Signals
- AI Stock Picker: No signal on given stock today.
- SwingMax: No signal on given stock recently.

Technical Analysis

Trend/structure: Bullish moving average stack (SMA_5 > SMA_20 > SMA_200) supports an ongoing uptrend.
Momentum: MACD histogram positive and expanding (0.0419) = bullish momentum building.
RSI: RSI(6) ~69.2 = near-overbought; upside can continue, but pullbacks/consolidation risk is elevated.
Key levels: Pivot 14.044 (price is slightly below/around this); resistance 14.691 (R1) then 15.091 (R2); support 13.396 (S1) then 12.996 (S2).
Short-term bias from pattern analogs: ~-0.41% next day, -0.91% next week, but +13.67% next month—supports buying for a multi-week push rather than expecting immediate acceleration.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning: Open interest is heavily tilted to calls (call OI 9,576 vs put OI 73; OI put/call 0.01) = strongly bullish skew.
Activity: Today’s volume is tiny (2 calls, 0 puts), so sentiment is more from positioning than fresh flow.
Volatility: 30D IV ~65.8% vs historical vol ~39.4% (IV elevated); IV percentile ~59 suggests options are not cheap, often consistent with event/earnings anticipation.

Technical Summary

Sell

Buy

Positive Catalysts

- Analysts remain constructive with Buy/Overweight stances and $15 targets (supports incremental institutional demand).
- Opioid claims settlement can reduce headline/legal overhang and improve visibility.
- Upcoming earnings: QDEC 2025 earnings on 2026-02-27 (pre-market) with EPS est. 0.16, which—if delivered—would signal improving profitability vs the very low recent EPS.

Neutral/Negative Catalysts

- Settlement headline includes potential up to $267M in cash/overdose treatment value—financial impact could pressure cash flows or sentiment depending on structure/timing.
- Latest reported quarter showed margin compression (gross margin down) and a sharp net income decline, which can cap multiple expansion until profitability stabilizes.
- Near-term technical: RSI near overbought + proximity to R1 (14.691) could cause stalling/retests before a clean break toward $15+.

Financial Performance

Latest quarter: 2025/Q3.
Revenue: $784.5M, +11.68% YoY (solid top-line growth).
Profitability: Net income $2.37M, -1618.59% YoY (major deterioration vs prior year comp).
EPS: $0.01 (flat/low), highlighting that revenue growth has not yet translated into strong earnings.
Gross margin: 34.92%, down ~8.99% YoY, indicating pricing/cost pressure.
Ownership/trading behavior: Hedge funds and insiders both Neutral recently (no strong confirmation from flows).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: Ratings are consistently positive with modest target increases/initiations.
2026-01-07 Truist: Reiterated Buy, raised PT $14 → $15, citing the attractive “affordable medicines” theme.
2025-12-08 Barclays: Initiated Overweight with $15 PT; highlights easing pricing headwinds and de-leveraging potential across the group.
Wall Street pros: Clear bullish framing around sector transition, improving sentiment, and AMRX as a beneficiary.
Wall Street cons: Targets are relatively tight around $15, implying limited upside beyond that level unless margins/earnings inflect meaningfully.
Political/congress activity: No recent congress trading data available; no politician/influential-figure trades provided.

4 Analyst Rating

Wall Street analysts forecast AMRX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMRX is 13.75 USD with a low forecast of 12 USD and a high forecast of 15 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 14.770

Low

Averages

13.75

High

Current: 14.770

Low

Averages

13.75

High

Truist

Buy

maintain

$14 -> $15

AI Analysis

2026-01-07

Reason

Truist

Price Target

$14 -> $15

AI Analysis

2026-01-07

maintain

Buy

Reason

Truist raised the firm's price target on Amneal Pharmaceuticals to $15 from $14 and keeps a Buy rating on the shares.The affordable medicines theme remains attractive heading into 2026, with Amneal offering a way to capture the opportunity, the analyst tells investors in a research note.

Barclays

Overweight

initiated

$15

2025-12-08

Reason

Barclays

Price Target

$15

2025-12-08

initiated

Overweight

Reason

Barclays initiated coverage of Amneal Pharmaceuticals with an Overweight rating and $15 price target. The firm rolled out coverage on the specialty pharmaceuticals industry with a neutral view, saying investor sentiment is improving as companies shift focus to innovation, margin expansion and de-leveraging. The group's pricing headwinds are easing while debt leverage is coming down, the analyst tells investors in a research note. Barclays sees "plenty of opportunity" as the sector "remains in a transition phase."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for AMRX

Unlock Now

AMRX Should I Buy

AMRX Should I Buy

Should You Buy Amneal Pharmaceuticals Inc (AMRX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch